Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680283 | 0.88 | — | — | |
| SCHEMBL18387218 | 0.86 | ATM (0.34) | ATM | |
| SCHEMBL10220848 | 0.86 | ATM (0.38) | ATM | |
| SCHEMBL679606 | 0.83 | ATM (0.34) | ATM | |
| SCHEMBL681239 | 0.83 | ATM (0.34) | ATM | |
| SCHEMBL681525 | 0.83 | ATM (0.34) | ATM | |
| SCHEMBL25450130 | 0.82 | ATM (0.41) | ATM | |
| SCHEMBL3434863 | 0.82 | ATM (0.41) | ATM | |
| SCHEMBL10205025 | 0.82 | ATM (0.41) | ATM | |
| SCHEMBL681120 | 0.79 | ALDH1A1 (0.37) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11746103-B2 | ALK-5 inhibitors and uses thereof | SUMITOMO PHARMA ONCOLOGY, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-10947205-B2 | Oxazolidinone compounds and methods of use thereof as antibacterial agents | MERCK SHARP & DOHME CORP. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20190248753-A1 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME LLC | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947205-B2 | Oxazolidinone compounds and methods of use thereof as antibacterial agents | OXA1L, ERAL1, TBCD | ATM 4316/4885 |
| US-20190248753-A1 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | OXA1L, ERAL1, TBCD | ATM 4316/4885 |
| US-11746103-B2 | ALK-5 inhibitors and uses thereof | ACVR1, ALK, ACVRL1 | ATM 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.